Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Anesthesiology Reports
Erschienen in: Current Anesthesiology Reports 2/2013

01.06.2013 | Neuromuscular Blockade (GS Murphy, Section Editor)

Sugammadex Development and Use in Clinical Practice

verfasst von: Claude Meistelman, Thomas Fuchs-Buder, Julien Raft

Erschienen in: Current Anesthesiology Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Sugammadex belongs to a new class of drug: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non-depolarizing muscle relaxants. The main advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However, it only works for reversal of rocuronium- or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium, the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine. Compared with neostigmine, reversal cost is significantly higher. However, economic aspects must take into account the reduction in recovery time and, more importantly, the prevention of residual paralysis in the PACU that can induce critical respiratory events and postoperative pulmonary complications.
Literatur
1.
Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130–7.PubMedCrossRef
2.
• Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Marymont JH, Vender JS, Gray J, Landry E, Gupta DK: Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology. 2011;115:946–54 This study highlights the use of objective monitoring of neuromuscular block to prevent residual paralysis in the PACU.
3.
Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98:1042–8.PubMedCrossRef
4.
Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology. 2010;112:1013–22.PubMedCrossRef
5.
Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future. 28;28:347–54.CrossRef
6.
Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002;41:266–70.PubMedCrossRef
7.
Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003;99:632–7.PubMedCrossRef
8.
Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104:667–74.PubMedCrossRef
9.
Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695–703.PubMedCrossRef
10.
Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104:555–62.PubMedCrossRef
11.
Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569–74.PubMedCrossRef
12.
Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth. 2006;96:36–43.PubMedCrossRef
13.
Vanacker BF, Vermeyen KM, Struys MM, Rietbergen H, Vandermeersch E, Saldien V, Kalmar AF, Prins ME. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg. 2007;104:563–8.PubMedCrossRef
14.
Duvaldestin P, Kuizenga K, Saldien V, Claudius C, Servin F, Klein J, Debaene B, Heeringa M. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg. 2010;110:74–82.PubMedCrossRef
15.
Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106:283–8.PubMedCrossRef
16.
• Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M: Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009;110:1020–5 This study demonstrates the interest of sugammadex for early reversal and its potential interest in the “cannot intubate cannot ventilate” situation.
17.
Beecher HK, Todd DP. A study of the deaths associated with anesthesia and surgery: based on a study of 599, 548 anesthesias in ten institutions 1948–1952, inclusive. Ann Surg. 1954;140:2–35.PubMedCrossRef
18.
Baillard C, Clec’h C, Catineau J, Salhi F, Gehan G, Cupa M, Samama CM. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth. 2005;95:622–6.PubMedCrossRef
19.
Arbous MS, Meursing AE, van Kleef JW, de Lange JJ, Spoormans HH, Touw P, Werner FM, Grobbee DE. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology. 2005;102:257–68.PubMedCrossRef
20.
Kopman AF, Zank LM, Ng J, Neuman GG. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg. 2004;98:102–6.PubMedCrossRef
21.
Blobner M, Eriksson LI, Scholz J, Motsch J, Della RG, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010;27:874–81.PubMedCrossRef
22.
Eikermann M, Vogt FM, Herbstreit F, Vahid-Dastgerdi M, Zenge MO, Ochterbeck C, de Greiff A, Peters J. The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. Am J Respir Crit Care Med. 2007;175:9–15.PubMedCrossRef
23.
Eriksson LI, Sundman E, Olsson R, Nilsson L, Witt H, Ekberg O, Kuylenstierna R. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology. 1997;87:1035–43.PubMedCrossRef
24.
McDonagh DL, Benedict PE, Kovac AL, Drover DR, Brister NW, Morte JB, Monk TG. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. Anesthesiology. 2011;114:318–29.PubMedCrossRef
25.
• Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, Hermens Y, Mirakhur RK: Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009; 110: 284–94 The first study providing data on the use and the efficacy of sugammadex in pediatric patients.
26.
•• Jones RK, Caldwell JE, Brull SJ, Soto RG: Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008; 109: 816–24 This study highlights the efficacy and rapidity of sugammadex to reverse deep levels of neuromuscular block.
27.
Sabo D, Jones RK, Berry J, Sloan T, Chen J, Morte JB, Groudine SB. Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium-induced blockade in patients undergoing abdominal surgery. J Anesth Clinic Res. 2011;2:140. doi:10,4172/​2155-6148.​1000140.
28.
Pansard JL, Chauvin M, Lebrault C, Gauneau P, Duvaldestin P. Effect of an intubating dose of succinylcholine and atracurium on the diaphragm and the adductor pollicis in humans. Anesthesiology. 1987;67:326–30.PubMedCrossRef
29.
Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles. Anesthesiology. 1990;73:870–5.PubMedCrossRef
30.
Kirov K, Motamed C, Dhonneur G. Differential sensitivity of abdominal muscles and the diaphragm to mivacurium: an electromyographic study. Anesthesiology. 2001;95:1323–8.PubMedCrossRef
31.
King M, Sujirattanawimol N, Danielson DR, Hall BA, Schroeder DR, Warner DO. Requirements for muscle relaxants during radical retropubic prostatectomy. Anesthesiology. 2000;93:1392–7.PubMedCrossRef
32.
Plaud B, Debaene B, Donati F. The corrugator supercilii, not the orbicularis oculi, reflects rocuronium neuromuscular blockade at the laryngeal adductor muscles. Anesthesiology. 2001;95:96–101.PubMedCrossRef
33.
• Paton F, Paulden M, Chambers D, Heirs M, Duffy S, Hunter JM, Sculpher M, Woolacott N: Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010; 105:558–67 The first pharmacoeconomics study on sugammadex for routine reversal.
34.
Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Hunter JM, Sculpher M, Woolacott N. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth. 2010;105:568–75.PubMedCrossRef
35.
Ledowski T, Hillyard S, Kozman A, Johnston F, Gillies E, Greenaway M, Kyle BC. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intensive Care. 2012;40:340–3.PubMed
36.
Watts RW, London JA, van Wijk RM, Lui YL. The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital. Anaesth Intensive Care. 2012;40:333–9.PubMed
37.
Raft J, Chenot ED, Longrois D, Meistelman C. Analysis of neuromuscular blocking drugs and sugammadex expenses, 1 year after its introduction into routine clinical practice. Ann fr Anesth Reanim. 2011;30:758–9.PubMedCrossRef
38.
Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010;113:1054–60.PubMedCrossRef
39.
Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg. 2007;104:582–4.PubMedCrossRef
40.
Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26:874–84.PubMedCrossRef
41.
Raft J, Harter V, Guerci P, Fuchs-Buder T., Meistelman, C. Biological evaluation of sugammadex on hemostasis and bleeding. Anesthesiology. 2012; A1009.
42.
• Dewachter P, Mouton-Faivre C, Emala CW: Anaphylaxis and anesthesia: controversies and new insights. Anesthesiology. 2009; 111:1141–50 A comprehensive general review on anaphylaxis during anesthesia and the role of NDMR.
43.
Fuchs-Buder T, Meistelman C, Alla F, Grandjean A, Wuthrich Y, Donati F. Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine. Anesthesiology. 2010;112:34–40.PubMedCrossRef
Metadaten
Titel
Sugammadex Development and Use in Clinical Practice
verfasst von
Claude Meistelman
Thomas Fuchs-Buder
Julien Raft
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Anesthesiology Reports / Ausgabe 2/2013
Elektronische ISSN: 2167-6275
DOI
https://doi.org/10.1007/s40140-013-0015-8

Weitere Artikel der Ausgabe 2/2013

Current Anesthesiology Reports 2/2013 Zur Ausgabe

Critical Care Anesthesia (LL Liu, Section Editor)

Goal Directed Fluid Resuscitation: A Review of Hemodynamic, Metabolic, and Monitoring Based Goals

Neuromuscular Blockade (GS Murphy, Section Editor)

Management Principles to Reduce the Risk of Residual Neuromuscular Blockade

Neuromuscular Blockade (GS Murphy, Section Editor)

Is Postoperative Residual Neuromuscular Block Associated with Adverse Clinical Outcomes? What Is the Evidence?

Critical Care Anesthesia (LL Liu, Section Editor)

ICU Management of Traumatic Brain Injury

Critical Care Anesthesia (LL Liu, Section Editor)

Care Bundles in the Adult ICU: Is It Evidence-Based Medicine?

Critical Care Anesthesia (LL Liu, Section Editor)

Early Mobilization in the Intensive Care Unit

Neu im Fachgebiet AINS

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Häufigste Gründe für Brustschmerzen bei Kindern

06.05.2024 Pädiatrische Diagnostik Nachrichten

Akute Brustschmerzen sind ein Alarmsymptom par exellence, schließlich sind manche Auslöser lebensbedrohlich. Auch Kinder klagen oft über Schmerzen in der Brust. Ein Studienteam ist den Ursachen nachgegangen.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise